Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPURPOSE trial of efavirenz in high-grade serous ovarian, fallopian tube, and primary peritoneal cancer
ACTRN12625001259437Phase 2Not yet recruiting
- Sponsor
- The University of Newcastle
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of efavirenz in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The University of Newcastle. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
efavirenz
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12625001259437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001259437.